CTS-2090

**CTS-2090** is a novel, potent, orally bioavailable, highly selective small molecule inhibitor of caspase-1, developed by Histogen Inc. as a potential first-in-class anti-inflammatory agent. It demonstrates potent oral activity in preclinical models of ulcerative colitis, providing statistically significant protection against inflammation-driven gastrointestinal tract damage and body weight loss, while showing no effect in apoptosis models, confirming its selectivity for inflammatory pathways over cell death processes. The compound is part of Histogen's pipeline of caspase inhibitors aimed at restoring immune function in inflammatory diseases, with drug-like properties enabling high intestinal exposure after oral dosing.[2][6][8]

Other names

CTS-2090CTS2090CTS 2090